Skip to content

Consumer exposure to an actual, dark-shaded oxidative hair dye. A [14C]-PPD labelled mass balance study*.

Consumer exposure to an actual, dark-shaded oxidative hair dye. A [14C]-PPD labelled mass balance study*. - Consumer exposure to PPD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON32506
Enrollment
16
Registered
2008-08-14
Start date
2008-09-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nvt. diit is een veiligheidsonderzoek systemic exposure (absorption)

Interventions

Intervention: A single typical hair dye procedure per subject will be performed by a professional hairdresser. Four professional hairdressers will be involved in the study.

Sponsors

TNO
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1:Female/Male; Age 18-45 years; 2:Healthy as assessed by health questionnaire, physical examination, clinical chemistry a pregnancy test in urine will be done. 3:Prescribed medication (oral contraceptives and paracetamol excluded) 4:Having given their written informed consent 5:Willing to have their coloured hair completely clipped (bald headed!) 6:Willing to refrain from blood donation during the whole study 7:Willing to use adequate measures to avoid pregnancy during the whole study (females only) 8:Willing to accept use of all anonymous data, including publication, and the confidential use and storage of all data 9: Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned 10: Willing to refrain from hair cutting to let grow their hair to about a 5 cm length on day 01 of the study

Exclusion criteria

Exclusion criteria: 1:Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study 2:Participation in any clinical trial or medical treatment including administration of a radiolabelled test substance up to 1 year before Day 01 of this study 3: Positive pregnancy test (urine) (females) or lactating 4: Prescribed medication (except oral contraceptives and paracetamol) 5: Alcohol consumption more than 28 units/week (males) or 21 units/week (females); 1 unit of alcohol equals 10 grams of ethanol 6:Having a known allergy to PPD 7: Having a positive response to the retro-auricular sensitisation test to PPD, conducted 2 days in advance of Day 01 of the study

Design outcomes

Primary

MeasureTime frame
Main study parameters/endpoints: The individual concentration of [14C]-radioactivity (recoveries) in all non-biological samples will be established and expressed as percentages relative to the applied dose. For biological (blood and urinary) samples, the individual concentration versus time courses of [14C]-radioactivity will be established and expressed as percentages relative to the applied dose; results will also be expressed as [14C]-PPDeq or as [14C]-PPDeq per unit of mass (g) or volume (mL).

Secondary

MeasureTime frame
Establishing a Mass Balance

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)